<div id="readability-page-1">02:40 PM EDT, 05/15/2026 (MT Newswires) -- Wave Life Sciences ( WVE ) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.Wedbush has an outperform rating and a $15 price target on Wave Life Sciences ( WVE ).Shares of the company were down 2.6% in Friday trading.Price: 6.72, Change: -0.18, Percent Change: -2.61 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

WAVE生命科學

動態生物技術與基因組 ETF - Invesco

2 倍做多納斯達克生物技術 ETF - ProShares

Wedbush Securities 預計 Wave Life Sciences 將在 2026 年 ATS 會議上展示其 RestorAATion-2 研究的數據，這可能會增強市場對其 RNA 編輯平台的信心。結果可能表明編輯效率的提高和持續的蛋白質反應，支持 α-1 抗胰蛋白酶的生產。儘管股價下跌 2.6% 至 6.72 美元，Wedbush 仍維持對 Wave Life Sciences 的 “跑贏大盤” 評級，目標價為 15 美元

Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says

fidelity

標普生物技術 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

納斯達克生物科技指數 ETF - iShares Nasdaq

生物技術臨牀實驗 ETF - LifeSci

基因改革 ETF - ARK

醫藥突破 ETF - ALPS

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

Wedbush 表示，WAVE 生命科學的 ATS 數據可能會支持其 RNA 編輯平台